Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 6 of about 6   

Articles published

DVAX 18.33 +0.78 (4.48%)
price chart
Dynavax Advances Agonist For Asthma Into The Clinic
Dynavax Technologies Corporation (NASDAQ:DVAX) announced this morning it will advance its proprietary second-generation TLR-9 agonist for asthma into Phase 1 clinical studies.
Related articles »  
85% Probability Of FDA Approval For Dynavax's Heplisav, Says Cowen's Senior ...
One of them is Dynavax Technologies (NASDAQ:DVAX), a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
6 Stocks Trading Under $5 on Winning Streaks
Dynavax Technologies Corporation (DVAX, Earnings, Analysts, Financials): A clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases.
Related articles »  
Risk Vs. Reward Never Gets Old
Everything one needs for a wild ride in a biotech company. The reason I like ... Dynavax Technologies has a number of promising drugs, with HEPLISAVTM being their prize, as it treats Hepatitis B, which afflicts 350 million people worldwide.
Small Cap Biotech Stocks With Hepatitis Exposure: ABT, BMY, GSK, GIL, JNJ ...
On the Hepatitis front, Dynavax Technologies Corporation product candidate is HEPLISAV - a Phase 3 investigational adult Hepatitis B vaccine that is designed to provide higher and earlier protection but with fewer doses than licensed vaccines.
Biodefense Industry - Market to Benefit from Federal Funding such as the BIO ...
7.2.1 Biodefense Contracts 31. 7.3 Bavarian Nordic 32. 7.3.1 Biodefense Contracts 32. 7.4 Cleveland BioLabs 33. 7.4.1 Biodefense Contracts 33.